3 results
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinb and metformin, combined with gemcitabine in patients with metatastatic pancreatic…
To determine the dose limiting toxicity (DLT) and the maximum tolerated dose and recommended dose of the combination of everolimus orally once daily and metformin orally BID to patients with advanced solid tumors.
The aim of our study is to compare one-year outcomes in terms of major adverse cardiovascular events (all cause death, reinfarction, any revascularization and stroke) of 2 different strategies in patients with non-STEMI and multivessel coronary…